OKYO Pharma (OKYO) Non-Current Assets (2021 - 2026)
OKYO Pharma (OKYO) posted quarterly Non-Current Assets of $6311.0 for Q1 2026, up 210.12% year-over-year from $2035.0 in Q1 2025, and up 435.74% quarter-over-quarter from $1178.0 in Q3 2025.
OKYO Pharma (OKYO) Non-Current Assets (2021 - 2026) Analysis & Trends
OKYO Pharma (OKYO) has reported Non-Current Assets for 6 consecutive years, with $6311.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Assets rose 210.12% year-over-year to $6311.0; the TTM figure through Mar 2026 stood at $123388.0 (up 5963.29% YoY), while the FY2026 annual figure was $6311.0, up 210.12% from the prior year.
- Non-Current Assets advanced to $6311.0 in Q1 2026 per OKYO's latest filing, from $1178.0 in the prior quarter.
- Across five years, Non-Current Assets topped out at $7216.0 in Q1 2023 and bottomed at $1178.0 in Q3 2025.
- Historically, Non-Current Assets has averaged $4076.6 across 5 years, with a median of $4245.0 in 2023.
- Annual changes were most pronounced in 2022 — Non-Current Assets tumbled 95.01% — and 2026, when it surged 210.12%.
- OKYO Pharma's Non-Current Assets stood at $5225.0 in 2022, then dropped by 1.63% to $5140.0 in 2023, then slumped by 58.02% to $2158.0 in 2024, then plunged by 45.41% to $1178.0 in 2025, then soared by 435.74% to $6311.0 in 2026.
- Business Quant data shows OKYO's Non-Current Assets at $6311.0 in Q1 2026, $1178.0 in Q3 2025, and $2035.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | OKYO Pharma | 1.52 Bn | 1.52 Bn | - | 6,311.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,311.00 |
| Sep 30, 2025 | 1,178.00 |
| Mar 31, 2025 | 2,035.00 |
| Sep 30, 2024 | 2,158.00 |
| Mar 31, 2024 | 3,350.00 |
| Sep 30, 2023 | 5,140.00 |
| Mar 31, 2023 | 7,216.00 |
| Mar 31, 2022 | 5,225.00 |
| Mar 31, 2021 | 104,636.00 |